Which of the Following Drug Is Most Likely to Have a Synergistic Effect When Combined With Radiation Therapy?

February 01, 2019

The Answer

The answer is D. Ipilimumab. 

Amifostine, pentoxifylline, and palifermin (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039571/) are all types of radioprotectants.   

Ipilimumab is a CTLA-4 inhibitor that has shown promise in clinical trials to improve some patients’ response to radiation therapy. Several recent trials (https://www.sciencedirect.com/science/article/pii/S2405630817300782) have suggested that combining radiation with immunotherapy, primarily checkpoint inhibitors, may have a synergistic effect on metastatic melanoma by preventing tumor cells from evading the immune response through several mechanisms.   

For more information about checkpoint inhibitors and how they work, watch a short video (https://www.youtube.com/watch?v=M2pTTDw0dtc&feature=youtu.be)

 


Copyright © 2019 by the Oncology Nursing Society. User has permission to print one copy for personal or unit-based educational use. Contact pubpermissions@ons.org for quantity reprints or permission to adapt, excerpt, post online, or reuse ONS Voice content for any other purpose.